Publications by authors named "Bong Tae Kim"
Article Synopsis
- The study aims to compare the effectiveness of tegoprazan, a new acid blocker, with esomeprazole in relieving nighttime heartburn and sleep disturbances in patients with gastroesophageal reflux disease (GERD).
- A total of 46 patients participated, receiving either tegoprazan 50 mg or esomeprazole 40 mg for 2 weeks, and although tegoprazan showed a faster time to first nighttime heartburn-free interval, the difference was not statistically significant.
- The results suggest that while tegoprazan might provide quicker relief from nighttime heartburn, more extensive studies are needed to confirm these findings due to the small sample size and significant limitations in statistical significance.
Background: Tegoprazan is a novel, fast- and long-acting potassium-competitive acid blocker that suppresses gastric acid secretion, which could benefit patients with non-erosive reflux disease (NERD), a type of gastroesophageal reflux disease.
Aim: To evaluate the efficacy and safety profiles of tegoprazan compared with those of a placebo in Korean patients with NERD.
Methods: In this phase 3, double-blind, placebo-controlled, multicentre study, 324 Korean patients with NERD were randomised into three treatment groups: tegoprazan 50 mg, tegoprazan 100 mg and placebo.
Tegoprazan, a novel potassium-competitive acid blocker (P-CAB), is a next-generation therapeutics developed for the treatment of acid-related gastrointestinal diseases such as gastroesophageal reflux disease (GERD) and peptic ulcers. In the present study, the in vitro and in vivo pharmacological properties of tegoprazan were compared with those of esomeprazole, a representative proton pump inhibitor. In vitro enzyme assays were performed using ion-leaky vesicles containing gastric H/K-ATPases isolated from pigs.
View Article and Find Full Text PDFRandomised phase 3 trial: tegoprazan, a novel potassium-competitive acid blocker, vs. esomeprazole in patients with erosive oesophagitis.
Aliment Pharmacol Ther
April 2019
Background: Tegoprazan is a novel potassium-competitive acid blocker that has a fast onset of action and can control gastric pH for a prolonged period, which could offer clinical benefit in acid-related disorders.
Aim: To confirm the non-inferiority of tegoprazan to esomeprazole in patients with erosive oesophagitis (EE).
Methods: In this multicentre, randomised, double-blind, parallel-group comparison study, 302 Korean patients with endoscopically confirmed EE (Los Angeles Classification Grades A-D) were randomly allocated to either tegoprazan (50 or 100 mg) or esomeprazole (40 mg) treatment groups for 4 or 8 weeks.